




## About Genmab

Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged transactional research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030 Genmab's vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO) antibody medicines.

## How we Operate



## At-a-glance

### Genmab's Growing Organization & Growing Presence

- Princeton, USA**
  - Translational Research
  - Development
  - U.S Market Operations
  - Corporate Functions
- Utrecht, NL**
  - Research
  - Translational Research
  - Antibody Product Creation
  - Corporate Functions
- Copenhagen, DK**
  - HQ
  - CMC Operations
  - Clinical Operations
  - Corporate Functions
- Tokyo, JP**
  - Japan Clinical
  - Japan Market Operations
  - Corporate Functions

### Our Strengths & Differentiators

- World-Class** antibody biology knowledge and deep insight into disease targets
- Discovery and development engine** with proprietary technologies that allow us to build a world-class pipeline
- In-house expertise** with solid track record of building successful strategic partnerships
- Robust pipeline** of potential best-in-class and first-in-class therapies
- Experienced, diverse** leadership team

## Operational

**8 Approved Medicines Including Genmab's Innovation**  
 Tivdak<sup>®</sup>, first Genmab owned product on market. Genmab owned, co-developed and co-promoted in partnership with Seagen EPKINLY<sup>™</sup> in partnership with AbbVie, second Genmab owned product on market  
 DARZALEX<sup>®</sup>, RYBREVANT<sup>®</sup>, TECVAYLI<sup>®</sup> and TALVEY<sup>™</sup> discovered and/or developed & marketed by Janssen  
 Kesimpta<sup>®</sup> developed & marketed by Novartis  
 TEPEZZA<sup>®</sup> developed & marketed by Horizon Therapeutics

**4 Proprietary\* Technologies**  
 DuoBody<sup>®</sup> platform, HexaBody<sup>®</sup> platform, DuoHexaBody<sup>®</sup> platform & HexElect<sup>®</sup> platform

**9 Proprietary\* Antibody Products in Clinical Development**  
 Tisotum vedotin, epcoritamab, DuoBody-PD-L1x4-1BB (GEN1046/BNT311), DuoBody-CD40x4-1BB (GEN1042/BNT312), HexaBody-CD27 (GEN1053/BNT313), GEN1056 (BNT322), DuoHexaBody-CD37 (GEN3009), HexaBody-CD38 (GEN3014), DuoBody-CD3xB7H4 (GEN1047)

**42 Cumulative INDs since 1999**  
 Created by Genmab or with Genmab's technologies

### 2022 Financials (DKK)

<b>194B</b>	<b>6,357M</b>	<b>14,595M</b>	<b>8,238M</b>
Year-end market cap	Operating Profit	Revenue	Operating Expenses 68% in R&D

## Our Purpose

Our unstoppable team will improve the lives of patients through innovative and differentiated antibody therapeutics

## Our Vision

By 2030, our KYSO antibody medicines are fundamentally transforming the lives of people with cancer and other serious diseases

## Our Values

- Passion for Innovation
- Determined - being the best at what we do
- Integrity - we do the right thing
- We work as one team & respect each other

## Our Strategy

- Focus on core competence
- Turn science into medicine
- Build a profitable and successful biotech

## Strong Pipeline of Potential 1st-in-class/Best-in-class Product Candidates

### Innovative Pipeline: Genmab's Proprietary<sup>1</sup> Products

Product	Developed By	Disease Indications	Most Advanced Development Phase				
			Pre-clinical	1	1/2	2	3
Tisotumab vedotin	Co-development Genmab / Seagen	Cervical cancer	█	█	█	█	█
		Solid tumors	█	█	█	█	█
Epcoritamab	Co-development Genmab / AbbVie	Relapsed/refractory DLBCL	█	█	█	█	█
		Relapsed/refractory FL	█	█	█	█	█
		First Line DLBCL	█	█	█	█	█
		B-cell NHL	█	█	█	█	█
		Relapsed/refractory CLL & Richter's Syndrome	█	█	█	█	█
		Indolent NHL pediatric patients	█	█	█	█	█
(DuoBody-PD-L1x4-1BB (GEN1046/BNT311))	Co-development Genmab / BioNTech	NSCLC	█	█	█	█	█
		Solid tumors	█	█	█	█	█
DuoBody-CD40x4-1BB (GEN1042/BNT312)	Co-development Genmab / BioNTech	Solid tumors	█	█	█	█	█
HexaBody-CD38 (GEN3014)	Genmab <sup>2</sup>	Hematologic malignancies	█	█	█	█	█
DuoHexaBody <sup>®</sup> -CD37 (GEN3009)	Genmab	Hematologic malignancies	█	█	█	█	█
DuoBody-CD3xB7H4 (GEN1047)	Genmab	Solid tumors	█	█	█	█	█
HexaBody-CD27 (GEN1053/BNT313)	Co-development Genmab / BioNTech	Solid tumors	█	█	█	█	█
GEN1056 (BNT322)	Co-development Genmab / BioNTech	Solid tumors	█	█	█	█	█

## Programs Incorporating Genmab's Innovation and Technology

### ≥Phase 2 Development<sup>3</sup>

Product	Target	Developed By	Disease Indications	Most Advanced Development Phase				
				Pre-clinical	1	1/2	2	3
Daratumumab	UltiMab <sup>®</sup>	Janssen	MM AL Amyloidosis	█	█	█	█	█
Teprotumumab	UltiMab	Horizon	Thyroid eye disease	█	█	█	█	█
Amivantamab	DuoBody	Janssen	NSCLC Adv. or metastatic gastric or esophageal cancer Adv. or metastatic colorectal cancer	█	█	█	█	█
Teclistamab	DuoBody	Janssen	MM	█	█	█	█	█
Talquetamab	DuoBody	Janssen	RRMM	█	█	█	█	█
Inclacumab	UltiMab	Pfizer (Global Blood Therapeutics)	Vaso-occlusive crises in sickle cell disease	█	█	█	█	█
Mim8	DuoBody	Novo Nordisk	Hemophilia A	█	█	█	█	█
Ordesekimab	UltiMab	Provention Bio	Celiac disease	█	█	█	█	█
Lu AF82422	UltiMab	Lundbeck	Multiple system atrophy	█	█	█	█	█

## Proprietary Technologies Allow us to Build a World-class Pipeline

### DuoBody Platform

- Bispecific antibody technology platform
- Potential in cancer, autoimmune, infectious, cardiovascular, central nervous system diseases and hemophilia
- Multiple commercial & research collaborations

### HexaBody Platform

- Enhanced potency antibody technology platform
- Broadly applicable technology that builds on natural antibody biology

### DuoHexaBody Platform

- Antibody technology that combines **DuoBody** and **HexaBody** platforms
- Creates bispecific antibodies with target mediated enhanced potency

### HexElect Platform

- Antibody technology platform inspired by **HexaBody** platform
- Combines dual targeting with enhanced selectivity & potency

### Executive Management

- Jan G. J. van de Winkel, Ph.D., President & CEO
- Anthony Pagano, EVP & CFO
- Judith Klimovsky, M.D., EVP & CDO
- Anthony Mancini, EVP & COO
- Tahamtan Ahmadi, M.D., Ph.D., EVP & CMO
- Birgitte Stephensen, EVP & CLO
- Christopher Cozic, EVP & CPO
- Martine J. van Vugt, Ph.D., EVP & CSO

### Notes

\*Tisotumab vedotin 50:50 partnership with Seagen; epcoritamab 50:50 partnership with AbbVie; DuoBody-PD-L1x4-1BB, DuoBody-CD40x4-1BB, HexaBody-CD27 and GEN1056 50:50 partnership with BioNTech; HexaBody-CD38, exclusive worldwide license and option agreement with Janssen Biotech, Inc.

1Certain product candidates in development with partners, as noted

2Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen Biotech, Inc.

3Products discovered and/or developed and marketed by others incorporating Genmab technology and innovation.

This document contains forward looking statements that involve significant risks and uncertainties. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on [www.genmab.com](http://www.genmab.com) and the risk factors included in Genmab's most recent Annual Report on form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at [www.sec.gov](http://www.sec.gov). August 11, 2023